Several monoclonal antibodies that specifically target EMMPRIN were tested in preclinical mouse models of pancreatic cancer [35,36], CML, hepatocellular carcinoma (HCC) [37], esophageal cancer [38] and non-small-cell lung carcinoma (NSCLC) [39]. The gene discussed is BSG; the disease is non-small cell lung carcinoma.